ACP
TVTX icon

Acuta Capital Partners’s Travere Therapeutics TVTX Stock Holding History

Acuta Capital Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-19,000
Closed -$266K – 48
2024
Q3 		$266K Buy
+19,000
New +$198K 0.22% 39
2016
Q3 		– Sell
-98,788
Closed -$1.76M – 78
2016
Q2 		$1.76M Sell
98,788
-101,212
-51% -$1.64M 0.85% 33
2016
Q1 		$2.73M Sell
200,000
-170,000
-46% -$2.58M 1.53% 23
2015
Q4 		$7.14M Buy
+370,000
New +$7.39M 3.41% 9

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Acuta Capital Partners's TVTX Position: Q4 2024 in Review

Acuta Capital Partners sold out of Travere Therapeutics (TVTX) in Q4 2024, closing a stake of 19,000 shares — an estimated $266K sold.

Acuta Capital Partners first reported a position in TVTX in Q4 2015 and held it in 4 quarters. The position peaked at $7.14M in Q4 2015. 197 funds tracked by Wall St. Rank hold TVTX as of Q4 2024.

  • Acuta Capital Partners reported no remaining Travere Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Acuta Capital Partners sold 19,000 Travere Therapeutics shares in Q4 2024, an estimated $266K.
  • Acuta Capital Partners first reported a position in Travere Therapeutics in Q4 2015 and held it in 4 quarters.
  • Acuta Capital Partners's Travere Therapeutics position peaked at $7.14M in Q4 2015.
  • 197 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2024.

Based on Acuta Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.